【藥品性質提示】 本品為公費藥品，需按疾管署公告適用對象處方，並於系統勾選適用對象。 疾管署公告內容：連結。 【藥品訊息】 公費 Relenza 吸入劑 5mg 衛教單張

抗病毒藥品 Influenza

 

Antiviral Agent; Neuraminidase Inhibitor

1. Absorption: ~4% to 17%
2. Distribution: Vd: ~16 L; Protein binding: <10%
3. Metabolism: None
4. Half-life elimination: 2.5 to 5.1 hours
5. Time to peak, plasma: 1 to 2 hours
6. Excretion: Urine (as unchanged drug); feces (unabsorbed drug)

Hypersensitivity to zanamivir or any component of the formulation (contains milk proteins)

Although neuraminidase inhibitors are currently recommended for the treatment or prophylaxis of influenza in pregnant women and women up to 2 weeks' postpartum, zanamivir is not the preferred agent.

Caution be exercised when administering zanamivir to breastfeeding women.

1. Central nervous system: Headache, Chills, Fatigue, Malaise, Dizziness
2. Gastrointestinal: Sore throat, Anorexia, decreased appetite, increased appetite, nausea, diarrhea, vomiting, abdominal pain
3. Infection: Viral infection
4. Respiratory: Nasal signs and symptoms, tonsil disease, cough, ENT infection, sinusitis, bronchitis, rhinitis
5. Dermatologic: Urticaria
6. Neuromuscular & skeletal: Myalgia, musculoskeletal pain, arthralgia, rheumatic disease
7. Miscellaneous: Fever

Prophylaxis:
Two inhalations (10 mg) once daily for 7 days after last known exposure
Treatment:
1. Two inhalations (10 mg) twice daily for 5 days.
2. Doses on first day should be separated by at least 2 hours; on subsequent days, doses should be spaced by ~12 hours.
3. Begin within 2 days of symptoms; Longer treatment may be considered for patients who remain severely ill after 5 days.

Infants ≥6 months and Children: 12 mg/kg as a single dose; maximum 600 mg/dose

No dosage adjustment necessary; however, the potential for drug accumulation should be considered.

There are no dosage adjustments provided in the manufacturer's labeling (has not been studied)

Store at 25°C